Memory loss, dementia and Medicare: what's actually covered

It usually starts small. A repeated question at dinner. A missed bill from someone who never missed bills. A phone call that covers the same ground as yesterday's. Families notice memory changes long before a doctor writes anything down — and the gap between noticing and getting real help is where months quietly disappear.

That gap is mostly a navigation problem, not a medical one. Medicare has meaningful dementia benefits, but they're scattered across different parts of the program, described in language nobody speaks at a kitchen table, and rarely offered proactively. This guide walks through them in order — from the first free screening to what happens if a claim is denied.

Every person on Medicare is entitled to an Annual Wellness Visit at no cost — and it includes a cognitive check. This is the single most useful and most skipped first step. It creates a documented baseline in the medical record, which is exactly what every later benefit, referral and appeal will be measured against.

If the screening raises concerns, the doctor can order a fuller cognitive assessment, and Medicare covers the diagnostic workup that follows — neurology visits, lab work, and brain imaging when a physician orders it. None of this requires paying out of pocket first and hoping for reimbursement later.

After a cognitive impairment diagnosis, Medicare covers a dedicated care-planning session — a real, scheduled visit where the doctor sits down with the patient and family to map out treatment, safety, medications, and what comes next. It exists precisely because a dementia diagnosis without a plan is just bad news.

In our experience this is one of the least-used benefits in all of Medicare. Providers don't always offer it, families don't know to ask, and so the plan never gets made. If there is one thing to take from this guide, it's this: after a diagnosis, request the care-planning visit explicitly.

The newest generation of Alzheimer's drugs — the infusion treatments designed to slow early-stage disease — are covered by Medicare, but with strings attached. Coverage generally requires treatment through providers participating in approved registries or studies, so CMS can track real-world results. A prescription alone is not enough; where and how the patient enrolls determines whether Medicare pays.

This is the step where families most often get blindsided: the neurologist recommends a drug, the infusion happens, and the claim comes back denied because the registry paperwork wasn't in place first. If a new treatment is on the table, confirm the registry enrollment before the first infusion — not after.

Neither is automatically better. Advantage plans sometimes include genuinely useful extras for dementia families — rides, meal support, caregiver programs — but they trade away flexibility in specialists and can add prior-authorization delays for imaging and new treatments. The right answer depends on the doctors involved and the stage of the disease, and it's worth a real comparison before enrollment windows close.

The pattern in every row is the same: the coverage existed, but nobody pointed at it. That's the quiet reality of dementia care in America — the system rarely says no outright. It just stays silent and lets families miss things.